Get the Stockscreener App
47.66
3.99%
-1.98
Pre-market:
47.20
-0.46
-0.97%
Twist Bioscience Corp stock is traded at $47.66, with a volume of 1.97M.
It is down -3.99% in the last 24 hours and up +25.29% over the past month.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
See More
Previous Close:
$49.64
Open:
$49.83
24h Volume:
1.97M
Relative Volume:
1.32
Market Cap:
$2.92B
Revenue:
$362.27M
Net Income/Loss:
$-85.19M
P/E Ratio:
-32.87
EPS:
-1.45
Net Cash Flow:
$-68.71M
1W Performance:
+1.19%
1M Performance:
+25.29%
6M Performance:
+73.62%
1Y Performance:
+5.05%
1-Day Range:
$46.96
$50.65
1-Week Range:
$46.17
$50.65
52-Week Range:
$23.30
$51.00
Twist Bioscience Corp Stock (TWST) Company Profile
Name
Twist Bioscience Corp
Sector
Industry
Phone
800-719-0671
Address
681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA
Compare TWST vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TWST
Twist Bioscience Corp
|
47.66 | 3.04B | 362.27M | -85.19M | -68.71M | -1.45 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Twist Bioscience Corp Stock (TWST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Initiated | Stephens | Overweight |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Jun-04-24 | Initiated | Guggenheim | Buy |
| Jan-17-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-27-23 | Initiated | Berenberg | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-29-21 | Initiated | William Blair | Outperform |
| Jun-04-21 | Initiated | Goldman | Neutral |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Feb-05-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-04-21 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-20 | Initiated | SVB Leerink | Mkt Perform |
| May-31-19 | Initiated | Evercore ISI | Outperform |
| Nov-26-18 | Initiated | JP Morgan | Neutral |
View All
Twist Bioscience Corp Stock (TWST) Latest News
Twist Bioscience Corporation (NASDAQ:TWST) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Twist's new DNA prep kits salvage low-quality genome samples - Stock Titan
Twist Bioscience (NASDAQ:TWST) Director Sells $105,402.00 in Stock - MarketBeat
Twist Bioscience shareholders approve director elections and executive compensation - Investing.com
Twist Bioscience shareholders approve director elections and executive compensation By Investing.com - Investing.com Australia
Twist Bioscience (TWST) Valuation After Q1 Beat And Raised 2026 Outlook - simplywall.st
Commit To Purchase Twist Bioscience At $37.50, Earn 27.6% Annualized Using Options - Nasdaq
Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus - Yahoo Finance
Assessing Twist Bioscience (TWST) Valuation After Recent Share Price Momentum - Yahoo Finance
Decoding Twist Bioscience Corp (TWST): A Strategic SWOT Insight - GuruFocus
6 Analysts Assess Twist Bioscience: What You Need To Know - Benzinga
TWST: Evercore ISI Group Raises Price Target on Twist Bioscience - GuruFocus
Barclays Raises Price Target for Twist Bioscience (TWST) to $50 - GuruFocus
These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results - Benzinga
Twist Bioscience Corporation $TWST Stake Raised by Thrivent Financial for Lutherans - MarketBeat
Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript - Insider Monkey
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - ChartMill
Twist Bioscience Corporation (TWST): A Bull Case Theory - Finviz
Twist Bioscience Corp SEC 10-Q Report - TradingView
Twist Bioscience Corp (TWST) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Twist Bioscience Q1 2026 slides: Revenue beats guidance, path to profitability accelerates By Investing.com - Investing.com South Africa
Why Is Twist Bioscience Stock Soaring Monday? - Benzinga
Twist Bioscience Corp (TWST) Q1 2026 Earnings Call Highlights: S - GuruFocus
Twist Bioscience (NASDAQ:TWST) Shares Gap UpStill a Buy? - MarketBeat
Twist Bioscience (TWST) Stock Surges Over 12% - GuruFocus
Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next - TechStock²
Twist Bioscience (TWST) Boosts Revenue Forecast, Shares Rise - GuruFocus
Twist Bioscience earnings missed by $0.07, revenue topped estimates - Investing.com Canada
Earnings call transcript: Twist Bioscience Q1 2026 sees revenue growth, stock surges - Investing.com India
Twist Bioscience Stock Climbs 7% Over Narrower Loss In Q1 - Nasdaq
Twist Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
TWIST BIOSCIENCE CORP (NASDAQ:TWST) Reports Mixed Q1 FY2026 Results with Revenue Beat and Wider Loss - ChartMill
Twist Bioscience (TWST) Surpasses Revenue Expectations in Q1 - GuruFocus
Twist Bioscience (TWST) Reports Q1 Revenue Beat, EPS Miss - GuruFocus
TWST Reports Impressive Revenue Growth in Latest Financial Update - GuruFocus
Twist Bioscience: Fiscal Q1 Earnings Snapshot - KVUE
Twist Bioscience (TWST) Raises Revenue Forecast for 2026 - GuruFocus
Twist Bioscience Q1 Earnings Report: What Investors Need to Know - Benzinga
Twist Bioscience stock rises 5% on revenue beat, raised guidance - Investing.com
Twist Bioscience Earnings Report: Q1 Overview - Benzinga
Twist Bioscience Corporation $TWST Shares Purchased by New York State Common Retirement Fund - MarketBeat
Twist Bioscience: Overview of First Fiscal Quarter Results - Bitget
Earnings Summary: Twist Bioscience Q1 - Benzinga
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results - Business Wire
Earnings Outlook For Twist Bioscience - Benzinga
Momentum Shift: Can Twist Bioscience Corporation deliver consistent EPS growthPortfolio Performance Report & High Accuracy Investment Signals - baoquankhu1.vn
cathie wood’s ARK stock trades: bullish and kodiak ai bought, kratos defense and twist bioscience sold - Investing.com South Africa
Cathie Wood Dumps Biotech Stocks, Loads Up on AI and Self-Driving Companies - CoinCentral
Cathie Wood’s ARK sells Twist Bioscience stock, buys Tempus AI and WeRide - Investing.com Nigeria
Cathie Wood’s ARK sells Twist Bioscience stock, buys Tempus AI and WeRide By Investing.com - Investing.com South Africa
Twist Bioscience Corp Stock (TWST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):